The Truth About Cholesterol — A 2026 Perspective
TL;DR The 2013 article was ahead of its time in highlighting inflammation and lifestyle as key drivers of heart disease. In 2026, the picture is more integrated: LDL/apoB lowering still saves lives and remains the primary strategy for high‑risk individuals, while inflammation explains residual risk and is now targeted through lifestyle, low‑dose colchicine, and emerging IL‑6 therapies. For individuals: focus on anti-inflammatory habits, get full risk assessment (LDL/apoB + hsCRP + imaging), and follow personalized medical advice. Cholesterol still matters — inflammation is the new layer on top. Back in 2013, this article argued that cholesterol alone wasn’t the full story behind heart disease — that inflammation, diet, and metabolic stress were major drivers. At the time, that view was ahead of the curve. A decade later, leading voices like Eric Topol and major cardiology societies now echo the same theme: atherosclerosis is both a lipid-driven and inflammation-driven disease. But th...